eligibility_summary
Eligible: newly diagnosed DLBCL with bulky mass (≥7.5 cm) and/or extranodal, any age, ECOG 0–2, adequate marrow (WBC≥3.5, ANC≥1.0, PLT≥75, Hb≥80), liver (AST/ALT≤2×ULN, TBILI≤2×ULN), renal (Ccr≥50), negative pregnancy test/non-lactating, effective contraception, life expectancy ≥6 mo, consent. Exclude: pregnancy/lactation, CNS disease, major heart disease/LVEF<50, ≥G2 neuropathy, active HBV/HCV/immunodeficiency, serious infection, neuro/psych illness, substance abuse, unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Standard R-CHOP immunochemotherapy followed by randomization to consolidation radiotherapy vs no RT. R-CHOP components/mechanisms: rituximab (chimeric anti-CD20 monoclonal antibody, type: biologic mAb, mediates ADCC, complement-dependent cytotoxicity, and direct apoptosis of CD20+ B cells), cyclophosphamide (alkylating agent, DNA crosslinking), doxorubicin (anthracycline, topoisomerase II inhibition, DNA intercalation, free-radical damage), prednisolone (glucocorticoid, induces lymphocyte apoptosis via glucocorticoid receptor). Radiotherapy: external beam consolidation to bulky/extranodal sites (30–36 Gy/15–18 fx) causing DNA double-strand breaks. Targets/pathways: malignant CD20+ diffuse large B cells, CD20-mediated immune clearance, DNA replication/repair stress (alkylation, topo II inhibition, RT-induced DSBs), oxidative damage, glucocorticoid receptor–driven apoptosis. Purpose: assess added value of RT after PET-CT complete remission.